Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
In the last 90 days, Protara Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Protara Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 30
- −1 vs. Q3 2023
- Shares held
- 4.36M
- −759.8K (−14.8%) vs. Q3 2023
- Total value
- $8.17M
- −$379.2K (−4.4%) vs. Q3 2023
- New holders
- 2
- 7 more added
- Sold out
- 3
- 6 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TARA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 119 | $176.0M |
| Q1 2026 | 114 | $237.4M |
| Q4 2025 | 105 | $212.3M |
| Q3 2025 | 81 | $114.0M |
| Q2 2025 | 76 | $90.1M |
| Q1 2025 | 59 | $123.8M |
| Q4 2024 | 60 | $156.6M |
| Q3 2024 | 35 | $19.1M |
| Q2 2024 | 38 | $22.2M |
| Q1 2024 | 34 | $18.3M |
| Q4 2023 | 30 | $8.17M |
| Q3 2023 | 31 | $8.55M |
| Q2 2023 | 29 | $12.3M |
| Q1 2023 | 29 | $16.9M |
| Q4 2022 | 30 | $14.7M |
| Q3 2022 | 31 | $16.7M |
| Q2 2022 | 33 | $18.4M |
| Q1 2022 | 35 | $33.2M |
| Q4 2021 | 38 | $46.5M |
| Q3 2021 | 36 | $43.7M |
| Q2 2021 | 40 | $69.3M |
| Q1 2021 | 50 | $134.0M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Protara Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Opaleye Management Inc. | 2,692,594 | $5.05M | 1.36% | 00.0% | Unchanged |
| Vanguard Group Inc | 427,612 | $801.8K | 0.00% | 00.0% | Unchanged |
| Boxer Capital, LLC | 209,227 | $392.3K | 0.02% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 199,671 | $374.4K | 0.00% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 188,664 | $352.8K | 0.10% | 00.0% | Unchanged |
| Privium Fund Management (UK) Ltd | 119,730 | $224.5K | 0.15% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 113,300 | $212.0K | 0.00% | +53,200+88.5% | Added |
| Geode Capital Management, LLC | 78,518 | $146.9K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 64,000 | $119.7K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 38,035 | $71.1K | 0.00% | +15,892+71.8% | Added |
| BlackRock Inc. | 34,316 | $64.3K | 0.00% | −286−0.8% | Reduced |
| State Street Corp | 30,900 | $57.8K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 27,018 | $50.7K | 0.00% | −800−2.9% | Reduced |
| Two Sigma Investments, LP | 25,145 | $47.1K | 0.00% | −2,200−8.0% | Reduced |
| Boothbay Fund Management, LLC | 18,864 | $35.4K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 18,127 | $34.0K | 0.00% | −2,460−11.9% | Reduced |
| Bank of New York Mellon Corp | 17,907 | $33.6K | 0.00% | 00.0% | Unchanged |
| Assenagon Asset Management S.A. | 15,831 | $29.7K | 0.00% | 00.0% | Unchanged |
| LPL Financial LLC | 12,000 | $22.5K | 0.00% | +2,000+20.0% | Added |
| Millennium Management LLC | 11,506 | $21.5K | 0.00% | −6,541−36.2% | Reduced |
| Acadian Asset Management LLC | 6,314 | $11.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 4,338 | $8.13K | 0.00% | −456−9.5% | Reduced |
| ADAR1 Capital Management, LLC | 2,194 | $4.11K | 0.00% | +2,194 | New |
| UBS Group AG | 916 | $1.72K | 0.00% | +795+657.0% | Added |
| Wells Fargo & Company | 569 | $1.07K | 0.00% | +4+0.7% | Added |
| Royal Bank of Canada | 728 | $1.00K | 0.00% | +228+45.6% | Added |
| Advisor Group Holdings, Inc. | 100 | $188 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 16 | $30 | 0.00% | +5+45.5% | Added |
| Bank of America Corp | 6 | $11 | 0.00% | +6 | New |
| Qube Research & Technologies Ltd | 2 | $4 | 0.00% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 0 | $0 | 0.00% | −772,584−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −34,971−100.0% | Sold out |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −13,821−100.0% | Sold out |